Compare · CELZ vs NU
CELZ vs NU
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and Nu Holdings Ltd. (NU): market cap, price performance, sector, and recent activity on the wire.
Summary
- CELZ operates in Health Care, while NU operates in Finance - the two are in different parts of the market.
- NU is the larger of the two at $56.37B, about 11335.8x CELZ ($5.0M).
- NU has been more active in the news (8 items in the past 4 weeks vs 1 for CELZ).
- NU has more recent analyst coverage (25 ratings vs 1 for CELZ).
- Company
- Creative Medical Technology Holdings Inc.
- Nu Holdings Ltd.
- Price
- -
- -
- Market cap
- $5.0M
- $56.37B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 8
- Recent ratings
- 1
- 25
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Nu Holdings Ltd.
Nu Holdings Ltd. operates in the technology industry. The company was incorporated in 2016 and is based in Grand Cayman, Cayman Islands.
Latest CELZ
- Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
- President & CEO Warbington Timothy was granted 1,000,000 shares (SEC Form 4)
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
- SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.
- SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.
Latest NU
- SEC Form 4 filed by Nu Holdings Ltd.
- SEC Form 4 filed by Nu Holdings Ltd.
- SEC Form 4 filed by Nu Holdings Ltd.
- SEC Form 4 filed by Nu Holdings Ltd.
- Monness Crespi & Hardt initiated coverage on Nu Holdings with a new price target
- Notice to Market: Nu Holdings Ltd.
- SEC Form 6-K filed by Nu Holdings Ltd.
- SEC Form 4 filed by Nu Holdings Ltd.
- US CEO and Chief Growth Offcr Junqueira Cristina Helena Zingaretti sold $375,363 worth of Class A ordinary shares ("Class A Shares") (25,000 units at $15.01) as part of a pre-agreed trading plan (SEC Form 4)
- Nu Holdings Ltd. Statement Regarding Media Reports